Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2020-10-19 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
PYC Equity Raising to Raise up to $55 Million 6 pages 380.8KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 20 October 2020 from PYC Therapeutics Limited regarding an equity raising to raise approximately A$55 million through a pro-rata accelerated non-renounceable entitlement offer and institutional placement. It details the offer structure, pricing, use of funds, timetable, and other related information. The content focuses on fundraising activities, share issuance, and capital structure changes. There are no financial statements or detailed financial performance data presented, nor is this a transcript, management report, or regulatory filing of another type. The document is clearly an update on capital raising activities, which fits the definition of a Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the equity raising, not just a brief notice or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2020-10-19 English
PYC Business and Equity Raising Presentation 28 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is an investor presentation dated 20 October 2020 by PYC Therapeutics Limited. It discusses a proposed $55 million offer of new shares, including a placement and entitlement offer, with detailed disclaimers, investment risks, and forward-looking statements. The content focuses on the capital raising activity and provides summary information for investors. There is no indication that this is a full financial report, audit, or earnings release. The document is not a regulatory filing or announcement of a report publication but a detailed presentation aimed at investors regarding financing. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-19 English
Trading Halt 3 pages 304.0KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from PYC Therapeutics Limited dated 16 October 2020. It specifically states that the securities will be placed in a trading halt pending the release of an announcement regarding a capital raising. The text references Listing Rules and the request for a trading halt, which is a regulatory compliance action related to capital raising activities. There is no financial data, detailed report, or presentation included, only a notice about the trading halt and the upcoming capital raising announcement. The document length is 3610 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2020-10-15 English
New Drug for Substantial Unmet Need Added to Pipeline 4 pages 239.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 12 October 2020 from PYC Therapeutics Limited. It discusses the addition of a new drug development program to the company's pipeline, focusing on a potential therapy for Autosomal Dominant Optic Atrophy (ADOA). The content is primarily an update on the company's drug development activities, intellectual property filings, and strategic progress. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The document is a corporate announcement about a new drug program and pipeline update rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it relates to the company's development pipeline and intellectual property filings, which are material to the company's capital and development strategy. The document length (9112 characters) and content support this classification with high confidence.
2020-10-11 English
Technical Presentation - October 2020 52 pages 4.5MB
Investor Presentation Classification · 95% confidence The document is a detailed technical presentation from October 2020 by PYC, an RNA therapeutics company. It includes extensive corporate overview, financial snapshot, board and management details, scientific and technical explanations of their RNA delivery platform, drug development pipeline, intellectual property status, and market opportunity for their lead drug candidate. The content is structured as a presentation with slides, figures, and detailed explanations aimed at investors or stakeholders. There is no indication that this is an official regulatory filing, audit report, earnings release, or legal proceeding. It is not a transcript of a call or a voting result announcement. The document is a comprehensive investor or corporate presentation focusing on company strategy, technology, pipeline, and market positioning. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-08 English
Notice of Directors intention not to seek re election at AGM 2 pages 87.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 9 October 2020 regarding a director's intention not to seek re-election at the upcoming Annual General Meeting. It specifically states that Doug Huey will step down as a director on the date of the AGM. There is no financial data, no report attached or referenced beyond this announcement, and the content focuses solely on a change in the company's board of directors. This matches the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is short and does not contain any financial statements or other report types. Therefore, the correct classification is MANG with high confidence.
2020-10-08 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.